Digostics, the UK-based health tech company behind the world's first oral glucose intolerance test (OGTT) that can be done at home instead of a clinic or hospital, has announced it has surpassed £500,000 in funding on the Crowdcube equity crowdfunding platform, with more than 100 investors backing the company's mission to revolutionise diabetes detection and monitoring.